TW202102221A - 維貝隆（ｖｉｂｅｇｒｏｎ）用於治療膀胱過動症之用途 - Google Patents

維貝隆（ｖｉｂｅｇｒｏｎ）用於治療膀胱過動症之用途 Download PDF

Info

Publication number
TW202102221A
TW202102221A TW109109041A TW109109041A TW202102221A TW 202102221 A TW202102221 A TW 202102221A TW 109109041 A TW109109041 A TW 109109041A TW 109109041 A TW109109041 A TW 109109041A TW 202102221 A TW202102221 A TW 202102221A
Authority
TW
Taiwan
Prior art keywords
individual
verbelon
average
placebo
treatment period
Prior art date
Application number
TW109109041A
Other languages
English (en)
Chinese (zh)
Inventor
保羅 小穆德
Original Assignee
瑞士商優洛凡特科學公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 瑞士商優洛凡特科學公司 filed Critical 瑞士商優洛凡特科學公司
Publication of TW202102221A publication Critical patent/TW202102221A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW109109041A 2019-03-18 2020-03-18 維貝隆（ｖｉｂｅｇｒｏｎ）用於治療膀胱過動症之用途 TW202102221A (zh)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US201962820230P 2019-03-18 2019-03-18
US62/820,230 2019-03-18
US201962830302P 2019-04-05 2019-04-05
US62/830,302 2019-04-05
US201962842435P 2019-05-02 2019-05-02
US62/842,435 2019-05-02
US201962885767P 2019-08-12 2019-08-12
US62/885,767 2019-08-12
US201962897019P 2019-09-06 2019-09-06
US62/897,019 2019-09-06
US201962904429P 2019-09-23 2019-09-23
US62/904,429 2019-09-23

Publications (1)

Publication Number Publication Date
TW202102221A true TW202102221A (zh) 2021-01-16

Family

ID=70166082

Family Applications (2)

Application Number Title Priority Date Filing Date
TW109109041A TW202102221A (zh) 2019-03-18 2020-03-18 維貝隆（ｖｉｂｅｇｒｏｎ）用於治療膀胱過動症之用途
TW113116798A TW202506129A (zh) 2019-03-18 2020-03-18 維貝隆（ｖｉｂｅｇｒｏｎ）用於治療膀胱過動症之用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW113116798A TW202506129A (zh) 2019-03-18 2020-03-18 維貝隆（ｖｉｂｅｇｒｏｎ）用於治療膀胱過動症之用途

Country Status (14)

Country Link
US (1) US20230027066A1 (https=)
EP (1) EP3941473A1 (https=)
JP (2) JP2022524576A (https=)
KR (2) KR20210142004A (https=)
CN (2) CN121489955A (https=)
AU (2) AU2020243514A1 (https=)
BR (1) BR112021017198A2 (https=)
CA (1) CA3129024A1 (https=)
IL (1) IL285910A (https=)
MX (1) MX2021009488A (https=)
PH (1) PH12021551975A1 (https=)
SG (1) SG11202108810YA (https=)
TW (2) TW202102221A (https=)
WO (1) WO2020188505A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3634420A1 (en) 2017-06-06 2020-04-15 Urovant Sciences GmbH Use of vibegron to treat overactive bladder
SG11202103662VA (en) 2018-12-05 2021-06-29 Urovant Sciences Gmbh Vibegron for the treatment of overactive bladder symptoms
TW202245781A (zh) * 2021-02-16 2022-12-01 瑞士商優洛凡特科學公司 用維貝格龍（ｖｉｂｅｇｒｏｎ）治療心臟衰竭之方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091825A1 (es) 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
ES2584427T3 (es) 2011-10-27 2016-09-27 Merck Sharp & Dohme Corp. Proceso para la preparación de agonistas beta 3 y productos intermedios
WO2013062881A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Process for making beta 3 agonists and intermediates
RS59402B1 (sr) 2013-03-15 2019-11-29 Merck Sharp & Dohme Postupak za pripremu beta 3 agonista i međuproizvoda
JP6197971B1 (ja) * 2016-04-22 2017-09-20 小野薬品工業株式会社 Ｋｃｎｑ２〜５チャネル関連疾患の予防および／または治療剤
US20170348288A1 (en) * 2016-06-03 2017-12-07 Velicept Therapeutics, Inc. Dosing regimens for beta-3 adrenoceptor agonists and anti-muscarinic agents for the treatment and prevention of lower urinary tract symptoms and overactive bladder
US10057209B2 (en) * 2016-07-28 2018-08-21 Qualcomm Incorporated Time-sequenced multi-device address assignment
JP7670461B2 (ja) * 2017-06-06 2025-04-30 ウロバント サイエンシズ ゲゼルシャフト ミット ベシュレンクター ハフトゥング 過活動膀胱の治療のためのビベグロンの投薬
EP3634420A1 (en) * 2017-06-06 2020-04-15 Urovant Sciences GmbH Use of vibegron to treat overactive bladder
EP3583905A1 (en) * 2018-06-20 2019-12-25 Arthrex Inc Percutaneous targeting device

Also Published As

Publication number Publication date
CN113840607A (zh) 2021-12-24
SG11202108810YA (en) 2021-10-28
AU2020243514A1 (en) 2021-08-26
AU2025256180A1 (en) 2025-11-13
MX2021009488A (es) 2021-09-21
TW202506129A (zh) 2025-02-16
WO2020188505A1 (en) 2020-09-24
CN121489955A (zh) 2026-02-10
JP2022524576A (ja) 2022-05-09
EP3941473A1 (en) 2022-01-26
JP2025084777A (ja) 2025-06-03
BR112021017198A2 (pt) 2021-11-16
CA3129024A1 (en) 2020-09-24
PH12021551975A1 (en) 2022-07-04
IL285910A (en) 2021-10-31
KR20210142004A (ko) 2021-11-23
KR20260049872A (ko) 2026-04-14
US20230027066A1 (en) 2023-01-26

Similar Documents

Publication Publication Date Title
JP2021506924A (ja) うつ病の治療のためのエスケタミン
US20090318469A1 (en) Use of Flibanserin for the Treatment of Sexual Disorders in Females
US20140343069A1 (en) Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
JP2026050474A (ja) Ｎｍｄａ拮抗薬の副作用の低減
JP2025084777A (ja) 過活動膀胱を処置するためのビベグロンの使用
JP2025032143A (ja) 良性前立腺肥大症の男性の過活動膀胱症状を治療するためのビベグロンの使用
US20230270738A1 (en) Methods of treating agitation associated with alzheimer's disease
JP2018150357A (ja) 治療レジメン
JP2024517937A (ja) Ｎｍｄａ受容体拮抗薬の副作用の低減
US20230131493A1 (en) Methods of treating agitation associated with alzheimer's disease
JP2006524708A (ja) 塩化トロスピウムの投与により連続睡眠を促進するための方法
US20130253067A1 (en) Method of treating bladder disorders
HK40126413A (en) Use of vibegron to treat overactive bladder symptoms in men with benign prostatic hyperplasia
TW202521100A (zh) 使用ｇｌｐ－１受體促效劑及第二活性劑之組合治療睡眠呼吸中止之方法及組合物
EA052961B1 (ru) Вибегрон для лечения симптомов гиперактивного мочевого пузыря